New Chairman for Redx

Redx Pharma, the Cheshire-headquartered research and development company focused on cancer, immunology and infection, has brought in a new chairman. The move to appoint Iain Ross comes a month after the Alderley Park business revealed plans to cut 80 jobs as part of a major restructuring.

Dr Neil Murray, Chief Executive Officer of Redx Pharma, commented on Iain’s appointment, “I am delighted to welcome Iain Ross to Redx Pharma as Chairman of the Board. His extensive experience in the life science sector makes him the ideal candidate to take on this role. I am confident that under his stewardship the Company will deliver shareholder value as we transition into a clinical-stage research and development company with a focus on cancer, immunology and infection.”

Iain Ross, incoming Chairman of Redx Pharma, commented on his appointment, “Redx Pharma is a business of the highest quality that has discovered high value assets in cancer, immunology and infection and the opportunity to be part of progressing these promising assets through the clinic was instantly appealing. I look forward to working with the Board to realise the value of our best-in-class assets, alongside several other promising assets in the Company’s pipeline.”

See more at RedxPharma.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.